Financings
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
Aptose Deal Closing Delayed to June; Hanmi Funding Secures Runway Amidst Regulatory Hurdles
Executive Summary
- Transaction Status: The Plan of Arrangement with Hanmi Pharmaceutical Co. Ltd. has been delayed from May 2026 to June 2026 due to pending Korean regulatory approvals.
- Closing Terms: Upon completion, Hanmi Purchasers will acquire all outstanding common shares not currently owned by them for C$2.41 in cash per share (a 28% premium over the 30-day VWAP of C$1.88).
- Financing Update: Aptose received an additional US$2.0 million advance from Hanmi under a US$11.9 million amended facility agreement. The final advance is expected shortly to complete the total facility value.
- Operational Continuity: Proceeds support uninterrupted continuance of the TUSCANY clinical trial (tuspetinib + venetoclax + azacitidine) for frontline treatment of newly diagnosed AML.
- Confidence Level: Parties do not anticipate that regulatory delays will prevent completion of the transaction.
Material Impact
- Deal Certainty: The delay introduces a short-term timeline extension but does not alter the fundamental value proposition (C$2.41 cash exit). Shareholder and court approvals were already secured in March 2026, reducing structural risk.
- Liquidity Risk Mitigation: The US$2.0 million advance is critical given Q1 2026 net losses of $7.6 million and a cash position of only $4.1 million as of March 31, 2026. This funding prevents immediate bankruptcy risk prior to closing.
- Market Sentiment: The stock price ($2.28) is trading slightly below the offer price ($2.41), indicating an arbitrage spread that may widen slightly due to the delay but remains tight enough to suggest high deal confidence.
- Routine Nature: This update follows previous delays announced in April 2026 (targeting May). The financing advance was part of the previously disclosed facility agreement terms, making this execution rather than a new strategic pivot.
APS · Price
Company Overview
- Company: Aptose Biosciences Inc., a clinical-stage biopharmaceutical company focused on oncology.
- Flagship Project: Tuspetinib (TUS), an oral pan-FGFR inhibitor.
- Clinical Program: TUSCANY Phase 1/2 trial evaluating tuspetinib in combination with venetoclax and azacitidine for frontline treatment of newly diagnosed AML patients ineligible for intensive chemotherapy.
- Data Highlights: Recent data (ASH 2025, EHA 2026) shows high response rates (90% overall CR/CRh; 100% at 80mg and 120mg doses) with favorable safety profiles across diverse mutational subtypes including TP53-mutated disease.
- Secondary Program: Luxeptinib program costs decreased as the trial is being wound down; license rights returned to CGI Invites Co., Ltd.
More from APTOSE BIOSCIENCES INC.
Jun 30, 2026 · 19:32